Bellicum Deal Enables Astellas To Progress PSCA Tech
This article was originally published in PharmAsia News
Bellicum has licensed in global rights to apply certain technology from Astellas to PSCA-targeting cell therapies for cancer, in a deal which helps the US firm take its first candidate in the field into the clinic next year, and enables Astellas to benefit from an area where it had previously discontinued some of its own projects.
You may also be interested in...
Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.